FDA Warns of Ocaliva Liver Injury Risks Linked to Autoimmune Disorder Drug
Federal regulators rejected full approval of Ocaliva in November following an analysis of post-marketing data by a committee of scientific advisors.
Federal regulators rejected full approval of Ocaliva in November following an analysis of post-marketing data by a committee of scientific advisors.